Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-99.93	-89.3	-111.57	-166.01	-174.52	-60.01
Depreciation & Amortization	1.15	1.25	1.37	1.17	0.49	0.01
Stock-Based Compensation	12.99	13.1	7.91	18.04	18.18	3.35
Other Adjustments	1.87	6.19	47.28	39.89	10.14	26.03
Changes in Accounts Payable	0.47	-2.92	-2.3	-7.8	14.49	1.96
Changes in Accrued Expenses	3.72	-1.42	-6.28	-9.32	17.54	4.51
Changes in Unearned Revenue	-6.31	-8.33	-15.45	33.56	-	-
Changes in Other Operating Activities	1.22	0.21	6.01	2.09	-3.37	-6.58
Operating Cash Flow	-84.68	-81.23	-73.02	-88.39	-117.04	-30.73
Capital Expenditures	-0.49	-0.37	-3.87	-20.62	-15.3	-0.08
Purchases of Intangible Assets	-	-	-3.5	-4.25	-6.25	-9
Other Investing Activities	0.14	0.01	0.02	-0.06	-	-
Investing Cash Flow	-0.34	-0.36	-7.35	-24.93	-21.55	-9.08
Long-Term Debt Issued	-	-	39.55	-	39.96	1.67
Long-Term Debt Repaid	-	-	-43	-	-	-1.67
Net Long-Term Debt Issued (Repaid)	-	-	-3.45	-	39.96	-
Issuance of Common Stock	107.5	76.87	140.86	53.5	-	165.85
Net Common Stock Issued (Repurchased)	107.5	76.87	140.86	53.5	-	165.85
Issuance of Preferred Stock	-	-	-	-	-	125.21
Net Preferred Stock Issued (Repurchased)	-	-	-	-	-	125.21
Other Financing Activities	-0.3	-0.19	-1.02	-1.4	-0.87	-
Financing Cash Flow	224.68	76.68	136.39	52.1	39.08	291.06
Net Cash Flow	139.66	-4.9	56.02	-61.22	-99.51	251.25
Free Cash Flow	-85.16	-81.6	-76.89	-109.01	-132.35	-30.81
FCF Margin	-1349.64%	-979.23%	-497.62%	-4356.87%	-	-
Free Cash Flow Per Share	-0.29	-0.33	-0.66	-2.48	-3.52	-1.74
Levered Free Cash Flow	-100.17	-100.89	-135.53	-166.94	-120.71	-60.2
Unlevered Free Cash Flow	-102.37	-103.06	-92.95	-163.38	-159.41	-43.19

Updated Nov 4, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q